MX2023002757A - Combinacion farmaceutica y tratamiento antitumoral. - Google Patents
Combinacion farmaceutica y tratamiento antitumoral.Info
- Publication number
- MX2023002757A MX2023002757A MX2023002757A MX2023002757A MX2023002757A MX 2023002757 A MX2023002757 A MX 2023002757A MX 2023002757 A MX2023002757 A MX 2023002757A MX 2023002757 A MX2023002757 A MX 2023002757A MX 2023002757 A MX2023002757 A MX 2023002757A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- protein kinase
- combination therapy
- treatment
- pharmaceutical combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 3
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 abstract 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003881 protein kinase C inhibitor Substances 0.000 abstract 2
- 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 abstract 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 abstract 1
- 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 abstract 1
- 101001072407 Homo sapiens Guanine nucleotide-binding protein subunit alpha-11 Proteins 0.000 abstract 1
- 102000003923 Protein Kinase C Human genes 0.000 abstract 1
- 108090000315 Protein Kinase C Proteins 0.000 abstract 1
- 201000005969 Uveal melanoma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describe una terapia de combinación que implica un inhibidor selectivo de la proteína cinasa C y un inhibidor de cMET, que es útil para el tratamiento contra el melanoma uveal metastásico y otras enfermedades proliferativas, tales como un tumor que tiene una mutación GNAQ o GNA11. La terapia de combinación puede proporcionarse mediante un producto farmacéutico, un método de tratamiento o un kit. La terapia de combinación puede implicar el uso de un inhibidor de la proteína cinasa C y un inhibidor de cMET. También se proporcionan métodos útiles para seleccionar pacientes o dirigir un plan de tratamiento. En diversos ejemplos, la proteína cinasa C puede tener la estructura de acuerdo con la Fórmula II.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075702P | 2020-09-08 | 2020-09-08 | |
| PCT/US2021/049310 WO2022055893A1 (en) | 2020-09-08 | 2021-09-07 | Pharmaceutical combination and tumor treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002757A true MX2023002757A (es) | 2023-07-25 |
Family
ID=80629827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002757A MX2023002757A (es) | 2020-09-08 | 2021-09-07 | Combinacion farmaceutica y tratamiento antitumoral. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4210704A1 (es) |
| JP (1) | JP2023541011A (es) |
| AU (1) | AU2021339579A1 (es) |
| CA (1) | CA3191363A1 (es) |
| IL (1) | IL300952A (es) |
| MX (1) | MX2023002757A (es) |
| WO (1) | WO2022055893A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023107894A1 (en) * | 2021-12-06 | 2023-06-15 | Ideaya Biosciences, Inc. | Combination therapy comprising a pkc inhibitor and a c-met inhibitor |
| WO2024044775A1 (en) * | 2022-08-26 | 2024-02-29 | Ideaya Biosciences, Inc. | Methods of treating uveal melanoma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| AU2012267888A1 (en) * | 2011-06-07 | 2014-01-30 | Caris Mpi, Inc. | Molecular profiling for cancer |
| JP6051434B2 (ja) * | 2011-11-14 | 2016-12-27 | イグニタ、インク． | ＡＸＬおよびｃ−ＭＥＴキナーゼ阻害剤としてのウラシル誘導体 |
| WO2014174478A1 (en) * | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| JO3589B1 (ar) * | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
-
2021
- 2021-09-07 WO PCT/US2021/049310 patent/WO2022055893A1/en active Application Filing
- 2021-09-07 JP JP2023515183A patent/JP2023541011A/ja active Pending
- 2021-09-07 EP EP21867451.3A patent/EP4210704A1/en active Pending
- 2021-09-07 AU AU2021339579A patent/AU2021339579A1/en active Pending
- 2021-09-07 MX MX2023002757A patent/MX2023002757A/es unknown
- 2021-09-07 IL IL300952A patent/IL300952A/en unknown
- 2021-09-07 CA CA3191363A patent/CA3191363A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4210704A1 (en) | 2023-07-19 |
| WO2022055893A1 (en) | 2022-03-17 |
| CA3191363A1 (en) | 2022-03-17 |
| IL300952A (en) | 2023-04-01 |
| JP2023541011A (ja) | 2023-09-27 |
| AU2021339579A1 (en) | 2023-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002757A (es) | Combinacion farmaceutica y tratamiento antitumoral. | |
| HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
| MX2010004074A (es) | Combinacion 059. | |
| NO20053649L (no) | Kombinasjonsterapi | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
| WO2009074827A3 (en) | Combination comprising a mek inhibitor and an aurora kinase inhibitor | |
| MX2021011928A (es) | Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras. | |
| MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
| HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
| WO2022197720A3 (en) | Compositions and methods for treating coronavirus infection | |
| NO20064754L (no) | Kombinasjonsterapi | |
| BRPI0412450A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular em um animal de sangue quente tal como um ser humano, e para o tratamento de um cáncer, composição farmacêutica, kit, e, uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd6126 ou um sal farmaceuticamente aceitável deste | |
| MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. | |
| BR0315087A (pt) | Métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6126 ou um sal deste farmaceuticamente aceitável e gencitabina |